<DOC>
	<DOCNO>NCT00517647</DOCNO>
	<brief_summary>The purpose study determine atomoxetine ( common brand name Strattera ) , medicine use treat old child Attention Deficit Hyperactivity Disorder ( ADHD ) , also safe helpful ADHD problem young child . While atomoxetine approve FDA use child young 6 year , FDA give permission study drug age group .</brief_summary>
	<brief_title>Atomoxetine Pilot Study Preschool Children With ADHD</brief_title>
	<detailed_description>Prevalence Attention Deficit Hyperactivity Disorder ADHD school age child estimate 2 % 11 % . Many preschool age child problem hyperactivity , short attention span , impulsivity behavior dyscontrol quite likely continue difficulty elementary school year . Many child refer diagnosis management difficult behavior diagnose ADHD . Children ADHD often display disruptive behavior interfere function school , home community due symptom hyperactivity , impulsiveness inattention . Symptoms ADHD may underdiagnosed undertreated preschool child . Preschool child ADHD often require vigilant monitoring supervision ensure safety . Symptoms impulsivity , hyperactivity distractibility often limit effectiveness educational behavioral intervention . Hence , important treat symptom ADHD child early age . Early intervention child ADHD may impact course illness abate longer-term disability vulnerable child . Pharmacological agent consider standard treatment recommendation child ADHD . Recently , non-stimulant pharmacological agent , atomoxetine ( ATMX ) , report effective safe school-age child ADHD . Data available usefulness ATMX child young 6 year . However , parent young child ADHD frequently ask practice physician prescribe ATMX child since want child take stimulant . There need carry treatment trial ATMX preschool child ADHD order collect data effective drug , safety , best dos administer child ADHD . Therefore , study pilot project obtain preliminary data use help set large study examine preschool child ADHD . All subject screen eligibility inclusion exclusion criterion . Since therapy include behavior therapy routinely indicate , ethical reason subject continue receive concurrent therapy throughout study period . All concurrent therapy stabilize minimum period 2 week prior child 's entry drug phase study . At medication follow-up visit , detailed history obtain record concurrent treatment . If child enrolls study , his/her participation last approximately 7 13 week minimum 7 outpatient daytime visit . The visit weekly begin every week child take optimum dose atomoxetine . Visits take 1-5 hour take place Department Psychiatry Arizona Health Sciences Center ( Tucson ) . The study consist 2 period . Screening assessment : The screen visit ( ) is/are use determine child eligible participation . The child 's teacher/daycare provider ( parent 's permission ) parent ( ) need complete form describe child 's problem overactivity , impulsivity inattention . The screening assessment may complete 1-2 visit . Each visit take 3-5 hour complete . The research staff evaluate child see s/he ADHD . Parents interview child 's behavior . The child 's teacher give several rating form complete . Parents ask complete question child 's development . Both parent ( available ) interview family history . After determined child eligible participate , baseline visit . The child 's previous ineffective medication discontinue . The rating do first visit repeat , include teacher parent rating scale . The child vital sign take include height , weight , blood pressure pulse rate , electrocardiogram ( EKG ) ( test heart rhythm record put sticky pad chest ) , urine test blood test ( 10cc 1 tablespoon ) . The doctor ask parent child 's medical history . Parents tell abnormal laboratory value physical finding may discover study . This information also available child 's pediatrician parent request do . Medication phase : After screen assessment complete , child enter medication phase study . The child start atomoxetine 0.5 mg/kg/day , dosage increase maximum dose 1.8 mg/kg/day . The dose determine well child responds tolerate drug . The dose give twice day minimize side effect . After optimum dose determine , child keep stable dose 4 week . At visit , vital sign take include height , weight , blood pressure , pulse rate . Interviews , play assessment , checklist , questionnaire complete visit order ass well child , whether symptoms side effect . Teachers also continue ask fill assessment . If child 's behavior get bad s/he experience side effect , parent call study doctor immediately determine change child 's treatment need make . Participants give card telephone number important information need get touch doctor time , day night . Some screening assessment videotaped/audiotaped . These tape use later cod , supervision child 's doctor/therapist , review offsite consultants/mentors , train doctors/therapists , and/or presentation conference . The tape erase time session parent 's request .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Child must 3669 month old time screen insure child complete shortterm safety efficacy trial age 6 year . Child must categorical dimensional evidence clinically significant ADHD symptom multiple setting present least six month . ADHD symptom must cause significant functional impairment child . Child must meet impairment scale threshold base Children 's Global Assessment Scale ( CGAS , Shaffer , Gould , Brasic et al. , 1983 ) score &lt; 60 . Child must reside primary caretaker least 6 month prior screen . Child 's heart rate must within 98th percentile blood pressure within 95th percentile age gender oral temperature value within normal range . Child prior fail treatment adequate trial ATMX ( define minimum 1.8 mg/kg/day 4 week ) know hypersensitivity ATMX . Prior failure stimulant psychotropics sole reason exclusion . Child take MAOI le 2 week since discontinue . Concurrent treatment medication CNS effect affect performance ( e.g. , antidepressant , antipsychotic , alphaagonists , adrenergic blocker , lithium carbonate , sedate antihistamine , decongestant sympathomimetics ) . Child previous psychotropic medication minimum duration one week stimulant , clonidine guanfacine ; two week bupropion , tricyclic antidepressant , venlafaxine , SSRIs ( except fluoxetine citalopram ) , valproate ; three week fluoxetine , citalopram , neuroleptic . Child narrow angle glaucoma . Child major medical condition would interfere involvement study would affect negatively ATMX ( i.e. , heart disease , high blood pressure , glaucoma , untreated unstable hyperthyroidism , uncontrolled seizure disorder , illness would require hospitalization ) . Child comorbid psychiatric diagnosis Major Depression , Bipolar Disorder , psychotic disorder , psychiatric disorder addition ADHD require concurrent treatment additional/alternative medication . Current history physical , sexual , emotional abuse . The patient take investigational drug within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ADHD</keyword>
	<keyword>atomoxetine</keyword>
	<keyword>preschool child</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>